Moderna's COVID-19 Vaccine Effective at Preventing Infection in Adolescents

Moderna Inc MRNA has announced that the Phase 2/3 study of its COVID-19 vaccine (mRNA-1273) in adolescents has met the primary endpoint of non-inferior immunogenicity versus the Phase 3 study adult comparator group.
In the study, no cases of COVID-19 were observed in participants who had received two doses of the vaccine.
Vaccine efficacy of 93% in seronegative participants was observed starting 14 days after the first dose.
The study, known as the TeenCOVE study, enrolled more than 3,700 participants ages 12 to less than 18 years in the U.S.
The Company plans to submit these data to regulators globally in early June.
mRNA-1273 was generally well-tolerated, and no significant safety concerns have been identified to date.
The majority of adverse events were mild or moderate in severity.
Price Action: MRNA shares up 2.55% at $168.35 during the premarket session on the last check Tuesday.

Momentum5.95

Growth-

Quality-

Value69.58

Short

Medium

Long